Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety, Tolerability and Pharmacokinetics Study of L608 in Healthy Adults — Stella

Recruiting

Back to Pulmonary Arterial Hypertension trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

New Zealand

NZCR Ltd (New Zealand Clinical Research), Christchurch

Key details

Phase

Early testing

Sponsor

Pharmosa Biopharm Inc.

Collaborators

Novotech (Australia) Pty Limited

Enrollment target

~32 participants

Started

April 2025

Primary completion

June 2026

Age range

18 Years – 65 Years

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov